Pacific Biosciences is trading 5.5% down at $1.36 as the stock extends a multi-day slide following a weak first-quarter earnings report and revenue shortfall.
- Shares remain under pressure after Q1 results revealed lower-than-expected revenue and persistent cash burn concerns.
- Market sentiment for the genomic sequencing firm remains fragile, even as broader technology indices trend higher during today's session.